<SEC-DOCUMENT>0001437749-25-031727.txt : 20251024
<SEC-HEADER>0001437749-25-031727.hdr.sgml : 20251024
<ACCEPTANCE-DATETIME>20251024161653
ACCESSION NUMBER:		0001437749-25-031727
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251024
DATE AS OF CHANGE:		20251024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275099
		FILM NUMBER:		251416414

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>bcda20251024_424b5.htm
<DESCRIPTION>FORM 424B5
<TEXT>
<html><head>
	<title>bcda20251024_424b5.htm</title>

	<!-- Generated by ThunderDome Portal - 10/24/2025 3:28:23 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed Pursuant to Rule 424(b)(5) </b><br>
<b>Registration No.</b> <b>333-275099</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PROSPECTUS SUPPLEMENT </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(To Prospectus dated December</b>&nbsp;<b>5, 2023 and the Prospectus Supplements dated December 6, 2023, December 2, 2024, April 4, 2025, and July 8, 2025) </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Up to $5,309,253</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="b01.jpg" src="b01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Common Stock </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023, as further supplemented by the prospectus supplements dated December 2, 2024,April 4, 2025, and July 8, 2025 (as further supplemented, the &#8220;Initial Prospectus Supplement&#8221;, and, collectively with the base prospectus, the &#8220;Prospectus&#8221;), relating to the sale of shares of our common stock, $0.001 par value per share, from time to time through H.C. Wainwright &amp; Co., LLC, as sales agent or principal, in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, pursuant to the Sales Agreement (as defined in the Prospectus).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;BCDA.&#8221; The last reported sale price of our common stock on the Nasdaq on October 23, 2025 was $1.395 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are filing this prospectus supplement to update the maximum aggregate offering amount of shares we are eligible to sell in this offering to $5,309,253, which amount is in addition to the approximately $3.9 million of gross proceeds we have received for sales of our common stock pursuant to the Sales Agreement under the Prospectus prior to the date of this prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The aggregate market value of our outstanding common stock held by non-affiliates is approximately $20.1&nbsp;million, based on 10,612,734 shares of outstanding common stock, of which 8,846,053 shares were held by non-affiliates, and a per share price of $2.27 based on the closing sale price of our common stock on September 11, 2025, which is the highest closing sale price of our common stock on the Nasdaq within the prior 60 days of this prospectus supplement. As a result, we are currently eligible to offer and sell up to an aggregate of approximately $5,309,253 of our securities under this prospectus supplement and the Prospectus. In no event will the aggregate offering amount of securities sold by us or on our behalf under this prospectus supplement pursuant to General Instruction I.B.6 of Form S-3 during the twelve-month period immediately prior to, and including, the date of any such sale, exceed one-third of the aggregate market value of our common stock held by non-affiliates in any 12 calendar month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. During the 12 calendar month period that ends on and includes the date hereof, we have sold approximately $1.4 million of our shares of common stock pursuant to General Instruction I.B.6 of Form S-3.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Investing in our common stock involves significant risk. You should review carefully the risk factors described in, and incorporated by reference under, </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page S-3 of the Initial Prospectus Supplement and page 3 of the accompanying base prospectus before investing in our common stock.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>H.C. Wainwright</b>&nbsp;<b>&amp; Co.</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The date of this prospectus supplement is October 24, 2025</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>b01.jpg
<TEXT>
begin 644 b01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z 7(# 2(  A$! Q$!_\0
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MS6O!^FZC#XOU2S%Q%N^SQ_<CY/ YZ4 >U7^H66G6K7%]<PV\*@Y>5PHKYO\
MB)XHF^)7BZSTKP[;RW5M:Y2#:IS*S$;G/]U> ,GTSWQ6UK/P$\0R([V_B)+]
MARL=V7!)^N2/TK'T'QUK_P --0DT;5/#=DFS'FK'$(I77/W@XR&!QU/% 'N7
M@3PM'X0\*6>E;@\Z@R7$@'WI#]X_0=![ 5U':N=\)^*]+\7:.-2TR0E2WERQ
MOP\3C^%A^/7OD5T= 'RO\+?^2P6/_7>X_P#07KZF) !R>*^6OA9_R5ZR_P"N
M]Q_Z"]?0'CW4&TOP)KMVA(=;1U!'4,PV@_AFA; ?.OCWQ/>>/?&H@LV+V:3B
MTTZ$9PQ+;=Y^I.<]AQVKZ2\)>&K7PKX<L])MA_JE#2R]Y9#]YC]37SG\%],%
M_P#$;3]YREG%)='(X) VC]7S^%?5= !1110!Y[\5_!D/B?PG<7448&I6"&:W
MD Y8#ED/U';U KS?X#>+9+36)/#-R^+6[#26P8_<E R5'U&3CU!-?1) (P>A
M]:^0-)<Z'\3[;[.<?9M7$:$\Y!DVG]&-(#Z*^)6JOI_A69(B5DN6$ (/(!SG
M]!^M<!\,M/6\\4^>P!6UB+@'^\3@'_T+\ZZ3XP,XM=-4?<\UL_7;Q_6L[X0E
M1JVH@_>\E/\ T)JQ;O-(]2DN3"MKJ>PCI11170>6+1112 2CL:.U4[V[CLK2
M:YF(6.)"['V IC2N['GWQ"NWU?6]+\+VQR9)5EN .RYX!_4UQLZR^#/&ZNF[
MRH) R\]86Z@G_/2NL^'5O)K>OZIXINQ]]S'!D=/7\A@8^M2?%?1O.L8-7B7Y
MH#Y<I']QN_X&N>2NN8]"A-1?LWLST6UGCGMXYHVW)(H92.X(XJSBN ^%NMF_
MT-M.F;,]B0G/4I_"?Z5WPK:#NKG%5AR3:9YM\8/^07I__7P?_035OX2_\BM+
MW_TJ3^E5/B^/^)7I^>GV@_\ H)JA\//%>C:-H+VE_?PP3&=G$;DYP<8/2L;I
M3U.Q1<L-9'JW(!KPGXF10Q>*[CR^"T"M(!Z\\_7 _E7;ZK\4--AB>/2DEOKD
M@[0B'9GW/^%<SH/@W5O$FLMJVO(\,$DGF,'&'DZ84#LO2G)\VB)P\?97E/0]
M3\-[O^$<T\OG<;:/.>OW17"?&#_CVTS_ *[-_P"@FO2XD"1A%&% P *\T^+_
M /QZZ;_UV;_T$TYKW",-*]:YK_"K_D4E_P"NS_S%=S7"_"C_ )%'_MN_]*[J
MJI_"C+$?Q6)C(P:\F^*'AR"!%UJ! A9Q'<8Z-G@''KGC\:]8)KDOB1&K^#;W
M=SMVL/KD8HJ*\6/#2:FO,S_A;K<FH:')93NSR6;A 3UV$?+S[<C\!6SX^X\&
M:E_UQ-<#\(Y677;^$$[&MPY';(8 ?H:[[Q]_R)FH_P#7(U$7>!M.*CB$EW..
M^#?^MUCZP_R:O5^_XUY3\'/];K'UA_DU>K=_QJJ7PF>*_BL8S!58GH!WKQ^Y
MM)/'7BC69T8_9;*$PVY!XW\X/T)!/T KMOB#KIT7PU,8FVW-Q^YBQUR>I'T&
M3^%,\ :)_9'A6 .I$UQ^^ESU!.,#\!C\<TIKF=@HMTX\YPWPNUAM.UZ;3)\H
MEUP%/\,BYX_$9S[@"O:!WKPGQUI\N@^+_MMJ=@F874)'9P?F'YX/XU['H.J1
MZQHUK?Q_=F0,1G[I[C\#D?A2I.UXFF*A>U1=36HHHK8XA****0'S9^T%_P C
MY9_]@Q/_ $9+7LGPL_Y)GH7_ %[C^9KQO]H'_D?+3_L&)_Z,EKV/X5_\DST/
M_KW'\S0@.P/0UY+\>M&@NO!T.K!%%U8W"@2=]C\$?GM/X>]>M=J\8^//BJUB
MT2+PQ!(KWEQ(LLZ@C]W&O(SZ$G'Y&F!S?[/E]+%XKU.P!)AN+/S67ME& !_)
MR*^B^U>$?L^:!,)-3\12QE8G46MNV/O<Y?\  $*/P->\4= /E?X6?\E@L?\
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M L2'L>Y_I^==EX^'_%&:E_UQ-3>$M 3P_H<-F"&E^_*X_B<\G_#Z 5%X]/\
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E7@8K$=X;<AZ=#V.1^5==S@]Z;'WI1]VB.B)J.[;'T4E%,@__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
